<DOC>
	<DOCNO>NCT01760798</DOCNO>
	<brief_summary>Osteoporosis characterize decrease bone strength prevalent among postmenopausal woman also occur men woman underlie condition major risk factor associate bone demineralization . Its chief clinical manifestation vertebral hip fracture , although fracture occur skeletal site.The World Health Organization ( WHO ) operationally defines osteoporosis bone density fall 2.5 standard deviation ( SD ) mean young healthy adult genderâ€”also refer T-score -2.5 . Postmenopausal woman fall low end young normal range ( T-score &gt; 1 SD mean ) define low bone density ( osteopenia ) also increase risk osteoporosis . More 50 % fracture , include hip fracture , among postmenopausal woman occur group . Teriparatide one effective treatment option osteoporosis . But cost teriparatide prohibitively expensive country like India limit personal resource individual , feasible option majority patient severe osteoporosis . The investigator aim compare weekly versus daily teriparatide therapy open label non inferiority trial successful , investigator anticipate , cost treatment could reduce considerably treatment become affordable large number patient . Also weekly therapy , number multiple injection could bring .</brief_summary>
	<brief_title>Weekly v Daily Teriparatide Therapy Severe Postmenopausal Osteoporosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Postmenopausal woman age group 5070 T score less 2.5 SD low lumbar spine proximal femur . Patients renal dysfunction ( serum creatinine &gt; 1.5 ) Primary secondary hyperparathyroidism Secondary osteoporosis Unexplained elevate ALP ( alkaline phosphatase ) History therapeutic radiation Active malignancy patient implant Patients receive i.v . oral bisphosphonates disease course</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>Teriparatide</keyword>
</DOC>